MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches across all sgRNA positions with near-zero ...
According to Precedence Research, the global gRNA market size is expected to grow from USD 708.92 million in 2025 to nearly ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
CRISPR, the gene-editing technology which won its creators the 2020 Nobel Prize for Chemistry, is most well-known for its ...
Both stocks are risky, but one is far less so. This juicy upside potential comes at a cost. Investors seeking stocks with ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...
Goldenberries taste like a cross between pineapple and mango, pack the nutritional punch of a superfood, and are increasingly ...
Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...
Biotech startup CrisprBits uses CRISPR-based techniques to change the shape of diagnostics by decoding genetic sequencing ...
To compete at iGEM, a sort of science Olympics, teens at a Georgia high school set their sights on finding a better way to ...
But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...